This directory lists 62 pharmaceutical bottle manufacturers across the United States, from specialized amber glass producers to high-volume high-density polyethylene (HDPE) blow molders.
Buyers in this category are typically solving critical problems related to drug product stability, patient safety, and stringent regulatory compliance. This involves securing containers that offer appropriate barrier properties for shelf-life, prevent chemical interaction via material compatibility, and are manufactured in environments adhering to current Good Manufacturing Practices (cGMP). The wrong choice can lead to failed stability studies, costly reformulation, or even regulatory rejection.
The types of suppliers in this space vary significantly, ranging from large, multi-national corporations offering extensive portfolios of standard containers and custom tooling services, to niche manufacturers specializing in specific materials like cyclic olefin copolymer (COC) or sterile-fill ready PETG. Some focus on specific closures like Child-Resistant Closures (CRCs), while others are vertically integrated, offering full-service design, molding, and secondary packaging solutions.
To effectively engage with these manufacturers, buyers should arrive prepared with detailed drug product characteristics, including dosage form, active pharmaceutical ingredient (API) properties, target shelf life, and anticipated regulatory submission type (e.g., IND, NDA, ANDA). Suppliers will expect precise specifications on bottle geometry, material requirements (e.g., HDPE, PET, PP, glass type), neck finish, and projected annual volumes to provide accurate and competitive quotes.
A significant trend in pharmaceutical bottle manufacturing is the increasing focus on sustainable packaging solutions, such as the incorporation of post-consumer recycled (PCR) content or the exploration of bioplastics, all while maintaining rigorous regulatory compliance and ensuring drug product integrity. Additionally, there's a growing demand for advanced barrier technologies and integrated functional closures to meet evolving drug delivery and patient compliance needs.